THE FACTORS ASSOCIATED WITH NATRIURETIC PEPTIDES (BNP AND NT-proBNP) TESTING IN PATIENTS PRESENTING TO EMERGENCY DEPARTMENTS OF ALBERTA WITH SUSPECTED HEART FAILURE

2015 ◽  
Vol 31 (10) ◽  
pp. S193
Author(s):  
N. Sepehrvand ◽  
J.A. Bakal ◽  
M. Lin ◽  
F.A. McAlister ◽  
J.C. Wesenberg ◽  
...  
2016 ◽  
Vol 32 (8) ◽  
pp. 986.e1-986.e8 ◽  
Author(s):  
Nariman Sepehrvand ◽  
Jeffrey A. Bakal ◽  
Meng Lin ◽  
Finlay McAlister ◽  
James C. Wesenberg ◽  
...  

2011 ◽  
Vol 7 (2) ◽  
pp. 104
Author(s):  
Kenneth McDonald ◽  
Ulf Dahlström ◽  
◽  

Heart failure (HF) is characterised by non-specific symptoms and unremarkable physical examination; therefore, the need exists for an available objective marker of HF status. Natriuretic peptides (NPs) are a marker that can aid the dilemmas in present-day HF management. More effective screening for clinical deterioration would include changes in brain natriuretic peptide (BNP) levels. Normal values for BNP, <50–100 pg/ml, have excellent negative predictive value (NPV) in excluding HF as a diagnosis. BNP values that are significantly elevated, e.g. >500 pg/ml, make the diagnosis of HF more likely. There are now established and emerging uses for NPs in managing HF in the community. These include the role of NPs at the time of possible new presentation of HF, its role in prognostication and, finally, the increasing interest in using NPs to guide therapy in the outpatient setting.


Sign in / Sign up

Export Citation Format

Share Document